D-1460-2019 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-1460-2019 was initiated by Macleods Pharma Usa Inc on Jun 20, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is terminated (terminated Oct 26, 2021). Affected quantity: 29106 bottles (2,619,540 tablets).

Recall details

Product Type
Drugs
Report Date
Jul 17, 2019
Initiation Date
Jun 20, 2019
Termination Date
Oct 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
29106 bottles (2,619,540 tablets)

Product description

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10

Reason for recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution pattern

Nationwide

Code information

BLL801A Dec-19 BLL802A Dec-19 BLL803A Dec-19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1460-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1460-2019. Report a data issue: hello@regdatalab.com.